Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meta10-19 in r/r DLBCL
NCT06120166Phase 1Recruiting
- Start
- Nov 2023
- Primary completion
- Dec 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Meta10-19 in diffuse large B-cell lymphoma (DLBCL). Primary endpoints: Maximum Tolerated Dose at 28 days and Objective Response Rate at 3 months. Started Nov 2023; status: recruiting.
02
Drugs
Meta10-19
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06120166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06120166.